The latest price and purchasing channels of landiolol in 2025

Landiolol is an ultra-short-acting cardioselective beta-1 adrenergic blocker, used for the short-term reduction of ventricular rate in adults with supraventricular tachycardia (including atrial fibrillation and atrial flutter). Supraventricular tachycardia is a heart condition characterized by an irregular, fast or erratic heartbeat.

Beta-1 adrenergic blockers are commonly used in the intensive care setting to control supraventricular tachycardia but may have the adverse effects of reducing cardiac contractility and lowering blood pressure. As a cardioselective beta-1 adrenergic blocker, landiolol reduces heart rate with minimal effects on myocardial contractility (inotropy) and minimal effects on blood pressure.

The U.S. Food and Drug Administration's (FDA's approval of landiolol was based on data from five randomized, double-blind, placebo-controlled studies that showed that patients treated with landiolol experienced a 40% to 90% reduction in heart rate in about 10 minutes, compared with a 0% to 11% reduction in heart rate in patients receiving placebo. The most common adverse effect of landiolol is hypotension.

Landiolol is administered by intravenous infusion in a monitored setting. Warnings and precautions associated with landiolol include risk of hypotension, bradycardia, and heart failure; risk of exacerbation of reactive airway disease; prevention of early warning signs of hypoglycemia in patients with diabetes and an increased risk of severe or prolonged hypoglycemia; and myocardial ischemia in patients with coronary artery disease.

As of 2025Landiolol’s original drug has not yet been officially launched in China, so its specific price and medical insurance-related information are still unclear. However, treatment costs with landiolol are often very expensive depending on overseas markets. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.

Reference materials:https://www.drugs.com/history/rapiblyk.html